Androclus Therapeutics Inc., of San Diego, received U.S. Patent No...Halozyme Therapeutics Inc., of San Diego, received a notice of allowance to both natural and recombinant forms of HTI-101, covering claims to a human enzyme normally found in the bloodstream with a mechanism of action that is distinct from its FDA-approved rHuPH20 enzyme...Introgen Therapeutics Inc., of Austin, Texas, was awarded U.S. Patent No

MediQuest Therapeutics Inc., of Bothell, Wash., was issued U.S. Patent No

Intranasal Therapeutics Inc., of Lexington, Ky., was issued U.S. Patent No

Acorda Therapeutics Inc., of Hawthorne, N.Y., received a patent on its neuregulins products, covering compositions of matter for the NRG2 family of growth factors, as well as methods of production for NRG2

Cell Therapeutics Inc., of Seattle, said the European Patent Office issued an allowance for its Xyotax patent, which will have the same term as an existing U.S

Androclus Therapeutics Inc., of San Diego, was granted U.S. Patent No

Metabasis Therapeutics Inc., of San Diego, was issued U.S. Patent No

Introgen Therapeutics Inc., of Austin, Texas, said the Board of Regents of the University of Texas System was issued U.S. Patent No

Introgen Therapeutics Inc., of Austin, Texas, was awarded U.S. Patent No

Cell Therapeutics Inc., of Seattle, received U.S. Patent No...Introgen Therapeutics Inc., of Austin, Texas, said U.S. Patent No

Cell Therapeutics Inc., of Seattle, was issued a notice of allowance for a patent application that includes coverage directed at Trisenox (arsenic trioxide) injection, its drug for acute promyelocytic leukemia...Esperion Therapeutics Inc., of Ann Arbor, Mich., was granted U.S. Patent No

6,627,190, which is exclusively sub-licensed to Introgen Therapeutics Inc., of Austin, Texas

Introgen Therapeutics Inc., of Austin, Texas, said U.S. Patent No

Amicus Therapeutics Inc., of New Brunswick, N.J., received U.S. Patent No

PharmaStem Therapeutics Inc., of Wayne, Pa., was issued U.S. Patent Nos

Critical Therapeutics Inc., of Cambridge, Mass., received U.S. Patent No

ChemGenex Therapeutics Inc., of Menlo Park, Calif., received a notice of allowance for its patent application titled "Naphthalimide Compositions and Uses Thereof

Lorus Therapeutics Inc., of Toronto, received a patent allowance titled "Antisense Oligonucleotide Sequences as Inhibitors of Microorganisms

Lorus Therapeutics Inc., of Toronto, was awarded a patent titled "Immunomodulating compositions for treatment of immune system disorders